Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression
top of page
Browse by category
Search
Tetra Pharm Technologies has reached a significant in developing its compound for appetite suppression, TPT0701, following the successful...
PROSS outcomes: Re-redo bariatric surgery is effective but carries significant risk of complications
Although Re-redo bariatric surgery is an effective treatment for obesity it carries a significant risk of complications, according to the...
Journal Watch 7/02/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Innovent's mazdutide accepted by China’s NMPA for chronic weight management
Innovent Biologics’ New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and...
FDA approves Veru’s trial with Enobosarm to treat muscle loss associated with weight loss drugs
The FDA has cleared Veru’s Investigational New Drug (IND) application for its Phase 2b clinical study to evaluate enobosarm, an oral...
Bariatric surgery most effective treatment for long-term hypertension
Bariatric surgery is more effective in controlling hypertension rates in people with obesity and uncontrolled high blood pressure...
‘Obesity, the Big Truth’ initiative is helping European healthcare professionals and patients better understand the science of obesity
The ‘Obesity, the Big Truth’ initiative provides a framework for physicians and surgeons to work alongside patient advocates to host...
Browse by tag
bottom of page